Insight journal - Dealtalk

Dealtalk: Novartis Chairman Says $10 Billion Acquisition Within Reach

Posted on 15 August 2013

Tags: , , ,

Novartis Chairman Joerg Reinhardt said a $10 billion purchase is possible as the drugmaker reviews its business, including units focused on animal health and vaccines, according to dealtalk.

Novartis is out of the bidding for Onyx Pharmaceuticals, according to the dealtalk.

Onyx’s current valuation made it too expensive, according to the dealtalk.

Novartis, AstraZeneca and Pfizer had expressed interest in Onyx, the biotechnology company said to have rebuffed an initial offer from Amgen according to previous dealtalk.

Onyx is involved with several potential purchasers, according to previous dealtalk.

Onyx rose 0.5 percent to $126.55 at 12:35 p.m. in New York, giving the company a market value of $9.29 billion.



Report: Partnering Deals and Alliances with Novartis

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply